Michael J. Thomas

Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

Ajay K. Kakkar, Mark N. Levine, Zbigniew Kadziola et al. · Journal of Clinical Oncology · 2004 · 654 citations · Full text

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Martin Reck, Alexander Luft, Aleksandra Szczęsna et al. · Journal of Clinical Oncology · 2016 · 526 citations

Antifibrotic Therapy, Oncology, Ipilimumab Plus Etoposide +14

Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression

Stéphane Potteaux, Emmanuel L. Gautier, Susan Hutchison et al. · Journal of Clinical Investigation · 2011 · 331 citations · Full text

Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol

Xuewei Zhu, J.S. Owen, Martha D. Wilson et al. · Journal of Lipid Research · 2010 · 327 citations · Full text

Innate Immune System, Immunology, Innate Immunity +22